These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31325263)

  • 21. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
    Chun JY; Kim K; Lee MK; Kang CK; Koh Y; Shin DY; Hong J; Choe PG; Kim NJ; Yoon SS; Park WB; Kim I; Oh MD
    BMC Infect Dis; 2021 Jan; 21(1):117. PubMed ID: 33499826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic vaccination with a live-attenuated herpes zoster vaccine in lung transplant candidates.
    Wang L; Verschuuren EAM; Paap D; Rondaan C; Raveling-Eelsing E; Westra J; Bos NA
    J Heart Lung Transplant; 2020 Dec; 39(12):1445-1454. PubMed ID: 33071180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older.
    Sutradhar SC; Wang WW; Schlienger K; Stek JE; Xu J; Chan IS; Silber JL
    Clin Vaccine Immunol; 2009 May; 16(5):646-52. PubMed ID: 19261769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.
    Beals CR; Railkar RA; Schaeffer AK; Levin Y; Kochba E; Meyer BK; Evans RK; Sheldon EA; Lasseter K; Lang N; Weinberg A; Canniff J; Levin MJ
    Lancet Infect Dis; 2016 Aug; 16(8):915-22. PubMed ID: 27061887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
    Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
    MacIntyre CR; Egerton T; McCaughey M; Parrino J; Campbell BV; Su SC; Pagnoni MF; Stek JE; Xu J; Annunziato PW; Chan IS; Silber JL
    Hum Vaccin; 2010 Nov; 6(11):894-902. PubMed ID: 20980796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial.
    Mok CC; Chan KH; Ho LY; Fung YF; Fung WF; Woo PCY
    Ann Rheum Dis; 2019 Dec; 78(12):1663-1668. PubMed ID: 31530556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation.
    Sasadeusz J; Prince HM; Schwarer A; Szer J; Stork A; Bock HL; Povey M; Nicholson O; Innis BL
    Transpl Infect Dis; 2014 Dec; 16(6):1024-31. PubMed ID: 25272081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
    Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
    Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL).
    Popmihajlov Z; Pang L; Brown E; Joshi A; Su SC; Kaplan SS; Willis ED
    Hum Vaccin Immunother; 2018; 14(12):2916-2920. PubMed ID: 30024827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study.
    Ohfuji S; Ito K; Inoue M; Ishibashi M; Kumashiro H; Hirota Y; Kayano E; Ota N
    BMC Infect Dis; 2019 Jan; 19(1):95. PubMed ID: 30691396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD008858. PubMed ID: 26937872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
    Willis ED; Woodward M; Brown E; Popmihajlov Z; Saddier P; Annunziato PW; Halsey NA; Gershon AA
    Vaccine; 2017 Dec; 35(52):7231-7239. PubMed ID: 29174682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herpes zoster vaccination in SLE: a pilot study of immunogenicity.
    Guthridge JM; Cogman A; Merrill JT; Macwana S; Bean KM; Powe T; Roberts V; James JA; Chakravarty EF
    J Rheumatol; 2013 Nov; 40(11):1875-80. PubMed ID: 24037550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates.
    Monslow MA; Elbashir S; Sullivan NL; Thiriot DS; Ahl P; Smith J; Miller E; Cook J; Cosmi S; Thoryk E; Citron M; Thambi N; Shaw C; Hazuda D; Vora KA
    Vaccine; 2020 Aug; 38(36):5793-5802. PubMed ID: 32703745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: a randomized controlled study.
    Mitra M; Faridi M; Ghosh A; Shah N; Shah R; Chaterjee S; Narang M; Bhattacharya N; Bhat G; Choudhury H; Kadhe G; Mane A; Roy S
    Hum Vaccin Immunother; 2015; 11(2):443-9. PubMed ID: 25692656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of varicella-zoster virus vaccine by different routes of administration: Comparable vaccination efficacy of one-fifth dose intradermal vaccination to conventional subcutaneous vaccination.
    Nakamura-Nishimura Y; Shinkuma S; Miyagawa F; Haredy A; Gomi Y; Yamanishi K; Asada H
    J Dermatol Sci; 2022 May; 106(2):86-92. PubMed ID: 35437206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
    Sanford M; Keating GM
    Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.